Xiaofei Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaofei Yu has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey Michael Friedman
Laboratory of Molecular Genetics, Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA
6 shared publications - Lora V. Hooper
Department of Immunology, University of Texas Southwestern Medical Center
5 shared publications Putianqi Wang
Laboratory of Molecular Genetics, Rockefeller University, New York, NY 10065, USA
5 shared publicationsChangchun Wang
State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China
4 shared publicationsLeah Kelly
Laboratory of Molecular Genetics, Rockefeller University, New York, NY 10065, USA
4 shared publicationsMengyu Xia
State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
4 shared publications
Latest Publications
- 12 February 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (3) , 524-526
Career pathways, part 19
- 12 February 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (3) , 524-526
Career pathways, part 19
- Open Access
- 3 December 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Alterations in short-chain fatty acid-associated gut microbiota and tight junction integrity in adolescent major depressive disorder
Major depressive disorder (MDD) often begins during adolescence, a critical developmental period during which nearly 50% of lifetime cases emerge. Despite its high prevalence and impact, objective diagnostic biomarkers for adolescent MDD remain limited, particularly those related to gut microbiota. Our study examined potential co-diagnostic biomarkers from peripheral blood and fecal samples in adolescents with MDD. We enrolled drug-naïve adolescents with first-episode MDD (n = 46, aged ≤18 years, 71.74% female) and age-/sex-matched healthy controls (HCs, n = 44). The levels of tight junction proteins (Claudin-5, Zonulin, FABP) and inflammatory biomarkers (IL-6, IL-8, TNF-α, and CRP) were markedly elevated in the plasma of adolescents with MDD, indicating gut barrier dysfunction and systemic inflammation. The microbiome in MDD patients exhibited a lower Firmicutes-to-Bacteroidetes ratio. At the genus level, Intestinimonas and Barnesiella were significantly enriched, while Dialister and Collinsella were considerably reduced. Integrating Collinsella abundance with tight junction proteins and inflammatory markers significantly improved diagnostic performance, achieving an area under the curve (AUC) of 0.964. Moreover, Collinsella negatively correlated with sex, Claudin-5, and TNF-α. Claudin-5 was strongly associated with short-chain fatty acids (SCFAs)-related pathways, including alanine, aspartate, glutamate metabolism, D-glutamine and D-glutamate metabolism, and autophagy regulation. Treatment of Caco-2 cells with propionate and butyrate confirmed the regulatory effects of SCFAs on tight junction biomarkers. These findings suggest the interplay between gut dysbiosis, barrier dysfunction, and inflammation in adolescent MDD and support microbiota-host biomarkers as a promising strategy for improving MDD diagnostic precision.
- 3 December 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessAlterations in short-chain fatty acid-associated gut microbiota and tight junction integrity in adolescent major depressive disorder
Major depressive disorder (MDD) often begins during adolescence, a critical developmental period during which nearly 50% of lifetime cases emerge. Despite its high prevalence and impact, objective diagnostic biomarkers for adolescent MDD remain limited, particularly those related to gut microbiota. Our study examined potential co-diagnostic biomarkers from peripheral blood and fecal samples in adolescents with MDD. We enrolled drug-naïve adolescents with first-episode MDD (n = 46, aged ≤18 years, 71.74% female) and age-/sex-matched healthy controls (HCs, n = 44). The levels of tight junction proteins (Claudin-5, Zonulin, FABP) and inflammatory biomarkers (IL-6, IL-8, TNF-α, and CRP) were markedly elevated in the plasma of adolescents with MDD, indicating gut barrier dysfunction and systemic inflammation. The microbiome in MDD patients exhibited a lower Firmicutes-to-Bacteroidetes ratio. At the genus level, Intestinimonas and Barnesiella were significantly enriched, while Dialister and Collinsella were considerably reduced. Integrating Collinsella abundance with tight junction proteins and inflammatory markers significantly improved diagnostic performance, achieving an area under the curve (AUC) of 0.964. Moreover, Collinsella negatively correlated with sex, Claudin-5, and TNF-α. Claudin-5 was strongly associated with short-chain fatty acids (SCFAs)-related pathways, including alanine, aspartate, glutamate metabolism, D-glutamine and D-glutamate metabolism, and autophagy regulation. Treatment of Caco-2 cells with propionate and butyrate confirmed the regulatory effects of SCFAs on tight junction biomarkers. These findings suggest the interplay between gut dysbiosis, barrier dysfunction, and inflammation in adolescent MDD and support microbiota-host biomarkers as a promising strategy for improving MDD diagnostic precision.
- Open Access
- 21 October 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Mediator Subunit MED16 Collaborates with UBP1-TFCP2 to Control Transcriptional Activation or Repression via Promoter Positional Specificity
The Mediator complex is an evolutionarily conserved transcriptional coactivator with well-characterized structure and function, though the roles of its dissociable subunits remain incompletely defined. Here, we demonstrate that Mediator subunit MED16 dissociates from the core complex to form a subcomplex with transcription factors UBP1 and TFCP2, and this interaction modulates transcriptional activation or repression in a context-dependent manner. Using protein purification coupled with mass spectrometry, we identified MED16 as a binding partner of UBP1-TFCP2. Gene expression analyses showed that UBP1 interacts with MED16 to activate a subset of silenced genes involved in lung homeostasis, angiogenesis, and cell proliferation. Conversely, the MED16-UBP1 interaction suppresses HIV-1 transcription, thereby reinforcing viral latency. Mechanistically, MED16 and UBP1 cooperatively bind the HIV-1 transcriptional start site (TSS) to inhibit preinitiation complex assembly. Genomic-scale analyses further demonstrated that transcription is activated when the UBP1-TFCP2 binding motif is proximal to the TSS, but repressed when the motif overlaps the TSS. Collectively, our findings identify a novel MED16-UBP1 interaction, define its dual role in transcriptional regulation, and highlight the therapeutic potential of targeting this axis in HIV-1 infection.
- 21 October 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Open AccessMediator Subunit MED16 Collaborates with UBP1-TFCP2 to Control Transcriptional Activation or Repression via Promoter Positional Specificity
The Mediator complex is an evolutionarily conserved transcriptional coactivator with well-characterized structure and function, though the roles of its dissociable subunits remain incompletely defined. Here, we demonstrate that Mediator subunit MED16 dissociates from the core complex to form a subcomplex with transcription factors UBP1 and TFCP2, and this interaction modulates transcriptional activation or repression in a context-dependent manner. Using protein purification coupled with mass spectrometry, we identified MED16 as a binding partner of UBP1-TFCP2. Gene expression analyses showed that UBP1 interacts with MED16 to activate a subset of silenced genes involved in lung homeostasis, angiogenesis, and cell proliferation. Conversely, the MED16-UBP1 interaction suppresses HIV-1 transcription, thereby reinforcing viral latency. Mechanistically, MED16 and UBP1 cooperatively bind the HIV-1 transcriptional start site (TSS) to inhibit preinitiation complex assembly. Genomic-scale analyses further demonstrated that transcription is activated when the UBP1-TFCP2 binding motif is proximal to the TSS, but repressed when the motif overlaps the TSS. Collectively, our findings identify a novel MED16-UBP1 interaction, define its dual role in transcriptional regulation, and highlight the therapeutic potential of targeting this axis in HIV-1 infection.
- Open Access
Mediator Subunit MED16 Collaborates with UBP1-TFCP2 to Control Transcriptional Activation or Repression via Promoter Positional Specificity
The Mediator complex is an evolutionarily conserved transcriptional coactivator with well-characterized structure and function, though the roles of its dissociable subunits remain incompletely defined. Here, we demonstrate that Mediator subunit MED16 dissociates from the core complex to form a subcomplex with transcription factors UBP1 and TFCP2, and this interaction modulates transcriptional activation or repression in a context-dependent manner. Using protein purification coupled with mass spectrometry, we identified MED16 as a binding partner of UBP1-TFCP2. Gene expression analyses showed that UBP1 interacts with MED16 to activate a subset of silenced genes involved in lung homeostasis, angiogenesis, and cell proliferation. Conversely, the MED16-UBP1 interaction suppresses HIV-1 transcription, thereby reinforcing viral latency. Mechanistically, MED16 and UBP1 cooperatively bind the HIV-1 transcriptional start site (TSS) to inhibit preinitiation complex assembly. Genomic-scale analyses further demonstrated that transcription is activated when the UBP1-TFCP2 binding motif is proximal to the TSS, but repressed when the motif overlaps the TSS. Collectively, our findings identify a novel MED16-UBP1 interaction, define its dual role in transcriptional regulation, and highlight the therapeutic potential of targeting this axis in HIV-1 infection.
Open AccessMediator Subunit MED16 Collaborates with UBP1-TFCP2 to Control Transcriptional Activation or Repression via Promoter Positional Specificity
The Mediator complex is an evolutionarily conserved transcriptional coactivator with well-characterized structure and function, though the roles of its dissociable subunits remain incompletely defined. Here, we demonstrate that Mediator subunit MED16 dissociates from the core complex to form a subcomplex with transcription factors UBP1 and TFCP2, and this interaction modulates transcriptional activation or repression in a context-dependent manner. Using protein purification coupled with mass spectrometry, we identified MED16 as a binding partner of UBP1-TFCP2. Gene expression analyses showed that UBP1 interacts with MED16 to activate a subset of silenced genes involved in lung homeostasis, angiogenesis, and cell proliferation. Conversely, the MED16-UBP1 interaction suppresses HIV-1 transcription, thereby reinforcing viral latency. Mechanistically, MED16 and UBP1 cooperatively bind the HIV-1 transcriptional start site (TSS) to inhibit preinitiation complex assembly. Genomic-scale analyses further demonstrated that transcription is activated when the UBP1-TFCP2 binding motif is proximal to the TSS, but repressed when the motif overlaps the TSS. Collectively, our findings identify a novel MED16-UBP1 interaction, define its dual role in transcriptional regulation, and highlight the therapeutic potential of targeting this axis in HIV-1 infection.
- Open Access
- 28 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (13)
Intravital imaging of translocated bacteria via fluorogenic labeling of gut microbiota in situ
The translocation of bacteria from intestinal tracts into blood vessels and distal organs plays pivotal roles in the pathogenesis of numerous severe diseases. Intravital monitoring of bacterial translocation, however, is not yet feasible, which greatly hinders us from comprehending this spatially and temporally dynamic process. Here we report an in vivo fluorogenic labeling method, which enables in situ imaging of mouse gut microbiota and real-time tracking of the translocated bacteria. By mimicking the peptidoglycan stem peptide in bacteria, a tetrapeptide probe composed of alternating D- and L-amino acids and separately equipped with a fluorophore and a quencher on the N- and C-terminal amino acid, is designed. Because of its resistance to host proteases, it can be directly used in gavage and achieves fluorogenic labeling of the microbiota in the gut via the functioning of the L,D-transpeptidases of the labeled bacteria. Using intravital two-photon microscopy, we then successfully visualize the translocation of gut bacteria into the bloodstream and liver in obesity mouse models. This technique can help further exploration into the spatiotemporal activities of gut microbiota in vivo, and be valuable in investigating the less understood pathogenicity of bacterial translocation in many severe diseases.
- 28 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (13)
Open AccessIntravital imaging of translocated bacteria via fluorogenic labeling of gut microbiota in situ
The translocation of bacteria from intestinal tracts into blood vessels and distal organs plays pivotal roles in the pathogenesis of numerous severe diseases. Intravital monitoring of bacterial translocation, however, is not yet feasible, which greatly hinders us from comprehending this spatially and temporally dynamic process. Here we report an in vivo fluorogenic labeling method, which enables in situ imaging of mouse gut microbiota and real-time tracking of the translocated bacteria. By mimicking the peptidoglycan stem peptide in bacteria, a tetrapeptide probe composed of alternating D- and L-amino acids and separately equipped with a fluorophore and a quencher on the N- and C-terminal amino acid, is designed. Because of its resistance to host proteases, it can be directly used in gavage and achieves fluorogenic labeling of the microbiota in the gut via the functioning of the L,D-transpeptidases of the labeled bacteria. Using intravital two-photon microscopy, we then successfully visualize the translocation of gut bacteria into the bloodstream and liver in obesity mouse models. This technique can help further exploration into the spatiotemporal activities of gut microbiota in vivo, and be valuable in investigating the less understood pathogenicity of bacterial translocation in many severe diseases.
- Open Access
- 15 November 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (12)
MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors
Dampened antigen presentation underscores the resistance of pancreatic cancer to T cell–mediated anti-tumor immunity, rendering immunotherapy largely ineffective. By high-throughput CRISPR activation perturbation, we discovered that the transcriptional regulator MCRS1 significantly augmented the sensitivity of mouse pancreatic cancer cells to T cell immunity in vitro and in vivo. Mechanistically, MCRS1 interacted with the transcription factor and genome organizer YY1 to coordinately increase the chromatin accessibility and expression of MHC-I genes. Elevated MCRS1 subverted MHC-I suppression and activated anti-tumor T cells, which sensitized mouse pancreatic cancer to α-PD-1 therapy. Remarkably, high MCRS1 expression was associated with increased T cell infiltration and extended survival of patients with pancreatic cancer and was predictive of favorable responses to α-PD-1 therapy in patients with lung cancer. Together, our study uncovers that MCRS1 sensitizes cancer cells to T cell immunity by transcriptionally subverting MHC-I suppression, which enhances the effectiveness of α-PD-1 therapy in mice and humans, paving the way to further improve immunotherapy against solid tumors.
- 15 November 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (12)
Open AccessMCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors
Dampened antigen presentation underscores the resistance of pancreatic cancer to T cell–mediated anti-tumor immunity, rendering immunotherapy largely ineffective. By high-throughput CRISPR activation perturbation, we discovered that the transcriptional regulator MCRS1 significantly augmented the sensitivity of mouse pancreatic cancer cells to T cell immunity in vitro and in vivo. Mechanistically, MCRS1 interacted with the transcription factor and genome organizer YY1 to coordinately increase the chromatin accessibility and expression of MHC-I genes. Elevated MCRS1 subverted MHC-I suppression and activated anti-tumor T cells, which sensitized mouse pancreatic cancer to α-PD-1 therapy. Remarkably, high MCRS1 expression was associated with increased T cell infiltration and extended survival of patients with pancreatic cancer and was predictive of favorable responses to α-PD-1 therapy in patients with lung cancer. Together, our study uncovers that MCRS1 sensitizes cancer cells to T cell immunity by transcriptionally subverting MHC-I suppression, which enhances the effectiveness of α-PD-1 therapy in mice and humans, paving the way to further improve immunotherapy against solid tumors.
- Open Access
- 11 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (41) , eadp9150
Bidirectional regulation of motor circuits using magnetogenetic gene therapy
Here, we report a magnetogenetic system, based on a single anti-ferritin nanobody-TRPV1 receptor fusion protein, which regulated neuronal activity when exposed to magnetic fields. Adeno-associated virus (AAV)–mediated delivery of a floxed nanobody-TRPV1 into the striatum of adenosine-2a receptor–Cre drivers resulted in motor freezing when placed in a magnetic resonance imaging machine or adjacent to a transcranial magnetic stimulation device. Functional imaging and fiber photometry confirmed activation in response to magnetic fields. Expression of the same construct in the striatum of wild-type mice along with a second injection of an AAVretro expressing Cre into the globus pallidus led to similar circuit specificity and motor responses. Last, a mutation was generated to gate chloride and inhibit neuronal activity. Expression of this variant in the subthalamic nucleus in PitX2-Cre parkinsonian mice resulted in reduced c-fos expression and motor rotational behavior. These data demonstrate that magnetogenetic constructs can bidirectionally regulate activity of specific neuronal circuits noninvasively in vivo using clinically available devices.
- 11 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (41) , eadp9150
Open AccessBidirectional regulation of motor circuits using magnetogenetic gene therapy
Here, we report a magnetogenetic system, based on a single anti-ferritin nanobody-TRPV1 receptor fusion protein, which regulated neuronal activity when exposed to magnetic fields. Adeno-associated virus (AAV)–mediated delivery of a floxed nanobody-TRPV1 into the striatum of adenosine-2a receptor–Cre drivers resulted in motor freezing when placed in a magnetic resonance imaging machine or adjacent to a transcranial magnetic stimulation device. Functional imaging and fiber photometry confirmed activation in response to magnetic fields. Expression of the same construct in the striatum of wild-type mice along with a second injection of an AAVretro expressing Cre into the globus pallidus led to similar circuit specificity and motor responses. Last, a mutation was generated to gate chloride and inhibit neuronal activity. Expression of this variant in the subthalamic nucleus in PitX2-Cre parkinsonian mice resulted in reduced c-fos expression and motor rotational behavior. These data demonstrate that magnetogenetic constructs can bidirectionally regulate activity of specific neuronal circuits noninvasively in vivo using clinically available devices.
- Top Cited Papers
- 19 July 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (8) , 1601-1615
Hydrogen sulfide produced by the gut microbiota impairs host metabolism via reducing GLP-1 levels in male mice
Dysbiosis of the gut microbiota has been implicated in the pathogenesis of metabolic syndrome (MetS) and may impair host metabolism through harmful metabolites. Here, we show that Desulfovibrio, an intestinal symbiont enriched in patients with MetS, suppresses the production of the gut hormone glucagon-like peptide 1 (GLP-1) through the production of hydrogen sulfide (H2S) in male mice. Desulfovibrio-derived H2S is found to inhibit mitochondrial respiration and induce the unfolded protein response in intestinal L cells, thereby hindering GLP-1 secretion and gene expression. Remarkably, blocking Desulfovibrio and H2S with an over-the-counter drug, bismuth subsalicylate, improves GLP-1 production and ameliorates diet-induced metabolic disorder in male mice. Together, our study uncovers that Desulfovibrio-derived H2S compromises GLP-1 production, shedding light on the gut-relayed mechanisms by which harmful microbiota-derived metabolites impair host metabolism in MetS and suggesting new possibilities for treating MetS.
- 19 July 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (8) , 1601-1615
Top Cited PapersHydrogen sulfide produced by the gut microbiota impairs host metabolism via reducing GLP-1 levels in male mice
Dysbiosis of the gut microbiota has been implicated in the pathogenesis of metabolic syndrome (MetS) and may impair host metabolism through harmful metabolites. Here, we show that Desulfovibrio, an intestinal symbiont enriched in patients with MetS, suppresses the production of the gut hormone glucagon-like peptide 1 (GLP-1) through the production of hydrogen sulfide (H2S) in male mice. Desulfovibrio-derived H2S is found to inhibit mitochondrial respiration and induce the unfolded protein response in intestinal L cells, thereby hindering GLP-1 secretion and gene expression. Remarkably, blocking Desulfovibrio and H2S with an over-the-counter drug, bismuth subsalicylate, improves GLP-1 production and ameliorates diet-induced metabolic disorder in male mice. Together, our study uncovers that Desulfovibrio-derived H2S compromises GLP-1 production, shedding light on the gut-relayed mechanisms by which harmful microbiota-derived metabolites impair host metabolism in MetS and suggesting new possibilities for treating MetS.
- 10 April 2024
- Published by Elsevier in Cell Host & Microbe
- Vol. 32 (4) , 450-452
GOSpel for tiny allies
- 10 April 2024
- Published by Elsevier in Cell Host & Microbe
- Vol. 32 (4) , 450-452
GOSpel for tiny allies